scholarly journals Effect of the dietary polyacetylenes falcarinol and falcarindiol on the gut microbiota composition in a rat model of colorectal cancer

2018 ◽  
Vol 11 (1) ◽  
Author(s):  
Morten Kobaek-Larsen ◽  
Dennis Sandris Nielsen ◽  
Witold Kot ◽  
Łukasz Krych ◽  
Lars Porskjær Christensen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Rat Model ◽  
Microbiota Composition ◽  
Gut Microbiota Composition

scholarly journals Association of dietary fibre intake and gut microbiota in adults

2018 ◽  
Vol 120 (9) ◽  
pp. 1014-1022 ◽  
Author(s):  
Daniel Lin ◽  
Brandilyn A. Peters ◽  
Charles Friedlander ◽  
Hal J. Freiman ◽  
James J. Goedert ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Gut Microbiota ◽  
Dietary Fibre ◽  
Meta Analysis ◽  
Microbiota Composition ◽  
Fibre Intake ◽  
Dietary Fibre Intake ◽  
The Relationship ◽  
Gut Microbiota Composition

AbstractIncreasing evidence indicates that gut microbiota may influence colorectal cancer risk. Diet, particularly fibre intake, may modify gut microbiota composition, which may affect cancer risk. We investigated the relationship between dietary fibre intake and gut microbiota in adults. Using 16S rRNA gene sequencing, we assessed gut microbiota in faecal samples from 151 adults in two independent study populations: National Cancer Institute (NCI), n 75, and New York University (NYU), n 76. We calculated energy-adjusted fibre intake based on FFQ. For each study population with adjustment for age, sex, race, BMI and smoking, we evaluated the relationship between fibre intake and gut microbiota community composition and taxon abundance. Total fibre intake was significantly associated with overall microbial community composition in NYU (P=0·008) but not in NCI (P=0·81). In a meta-analysis of both study populations, higher fibre intake tended to be associated with genera of class Clostridia, including higher abundance of SMB53 (fold change (FC)=1·04, P=0·04), Lachnospira (FC=1·03, P=0·05) and Faecalibacterium (FC=1·03, P=0·06), and lower abundance of Actinomyces (FC=0·95, P=0·002), Odoribacter (FC=0·95, P=0·03) and Oscillospira (FC=0·96, P=0·06). A species-level meta-analysis showed that higher fibre intake was marginally associated with greater abundance of Faecalibacterium prausnitzii (FC=1·03, P=0·07) and lower abundance of Eubacterium dolichum (FC=0·96, P=0·04) and Bacteroides uniformis (FC=0·97, P=0·05). Thus, dietary fibre intake may impact gut microbiota composition, particularly class Clostridia, and may favour putatively beneficial bacteria such as F. prausnitzii. These findings warrant further understanding of diet–microbiota relationships for future development of colorectal cancer prevention strategies.

scholarly journals Host–MicroRNA–Microbiota Interactions in Colorectal Cancer

Genes ◽  
2019 ◽  
Vol 10 (4) ◽  
pp. 270 ◽  
Author(s):  
Ce Yuan ◽  
Clifford J. Steer ◽  
Subbaya Subramanian
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Tumor Cells ◽  
Immune Cell ◽  
Review Article ◽  
Microbiota Composition ◽  
Cell Fractions ◽  
High Level ◽  
Gut Microbiota Composition

Changes in gut microbiota composition have consistently been observed in patients with colorectal cancer (CRC). Yet, it is not entirely clear how the gut microbiota interacts with tumor cells. We know that tumor cells undergo a drastic change in energy metabolism, mediated by microRNAs (miRNAs), and that tumor-derived miRNAs affect the stromal and immune cell fractions of the tumor microenvironment. Recent studies suggest that host intestinal miRNAs can also affect the growth and composition of the gut microbiota. Our previous CRC studies showed a high-level of interconnectedness between host miRNAs and their microbiota. Considering all the evidence to date, we postulate that the altered nutrient composition and miRNA expression in the CRC microenvironment selectively exerts pressure on the surrounding microbiota, leading to alterations in its composition. In this review article, we present our current understanding of the role of miRNAs in mediating host–microbiota interactions in CRC.

scholarly journals Effects of Prebiotic Supplement on Gut Microbiota, Drug Bioavailability and Adverse Effects in Patients with Colorectal Cancer at Different Primary Tumor Locations Receiving Chemotherapy: Study Protocol for a Randomized Clinical Trial

2022 ◽  
Author(s):  
Yanmin Li ◽  
Hong Cao ◽  
Bojian Fei ◽  
Chuanqing Bao ◽  
Jianmin Xu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Adverse Effects ◽  
Gut Microbiota ◽  
Primary Tumor ◽  
Response To Therapy ◽  
Control Group ◽  
Microbiota Composition ◽  
Drug Bioavailability ◽  
Gut Microbiota Composition

Abstract Background: The prevalence of colorectal cancer (CRC) worldwide is a huge challenge to human health. Primary tumor locations found to impact prognosisand response to therapy. The important role of gut microbiota in the progression and treatment of CRC has led to many attempts of alleviating chemotherapy-induced adverse effects using microecologics. However, the underlying mechanism of the difference in the prognosis of different primary tumor locations and the synergistic effect of prebiotics on chemotherapy need to be further elucidated. This study aims to explore the differences in tumor microbiota and examine the effectiveness of xylooligosaccharides (XOS) on gut microbiota, adverse effects, and bioavailability of chemotherapy drugs in CRC patients at different primary tumor locations.Methods: This is a double-blinded, randomized, parallel controlled clinical trial. Participants with left-sided CRC (LSCRC, n = 50) and right-sided CC (RSCC, n = 50) will randomly allocated to prebiotic group (n = 25) or control group (n = 25) and will receive either a daily XOS (3 g/d) or placebo, respectively, for 12 weeks. The primary outcomes will be the differences in the mucosa microbiota composition at different tumor locations, and differences in gut microbiota composition, adverse effects, and blood concentration of capecitabine posttreatment. The secondary outcomes will include other blood indicators, short-chain fatty acids (SCFAs) concentration, quality of life, and mental health.Discussion: This study will reveal the potential benefits of prebiotic for improving the gut microbiota composition, alleviating the adverse effects, and improving the efficacy of chemotherapy in patients with CRC. In addition, this study will provide data on the different distribution of tumor microbiota and the different changes of gut microbiota during treatment in LSCRC and RSCC, which may provide novel insights into personalized cancer treatment strategies based on primary tumor locations and gut microbiota in the future.Trial registration: Chinese Clinical Trial Registry(www.chictr.org.cn): ChiCTR2100046237. Registered on 12 May 2021.

scholarly journals Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 43
Author(s):  
Asimina Koulouridi ◽  
Ippokratis Messaritakis ◽  
Nikolaos Gouvas ◽  
John Tsiaoussis ◽  
John Souglakos
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity ◽  
Gut Microbiota ◽  
Solid Tumors ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Immune Surveillance ◽  
Microbiota Composition ◽  
Innate And Adaptive Immunity ◽  
Gut Microbiota Composition

Over the last few years, immunotherapy has been considered as a key player in the treatment of solid tumors. Immune checkpoint inhibitors (ICIs) have become the breakthrough treatment, with prolonged responses and improved survival results. ICIs use the immune system to defeat cancer by breaking the axes that allow tumors to escape immune surveillance. Innate and adaptive immunity are involved in mechanisms against tumor growth. The gut microbiome and its role in such mechanisms is a relatively new study field. The presence of a high microbial variation in the gut seems to be remarkably important for the efficacy of immunotherapy, interfering with innate immunity. Metabolic and immunity pathways are related with specific gut microbiota composition. Various studies have explored the composition of gut microbiota in correlation with the effectiveness of immunotherapy. Colorectal cancer (CRC) patients have gained little benefit from immunotherapy until now. Only mismatch repair-deficient/microsatellite-unstable tumors seem to respond positively to immunotherapy. However, gut microbiota could be the key to expanding the use of immunotherapy to a greater range of CRC patients.

The chemopreventive effects of Huangqin-tea against AOM-induced preneoplastic colonic aberrant crypt foci in rats and omics analysis

2020 ◽  
Vol 11 (11) ◽  
pp. 9634-9650
Author(s):  
Jie Shen ◽  
Pei Li ◽  
Shuangshuang Liu ◽  
Qing Liu ◽  
Yue Li ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Rat Model ◽  
Aberrant Crypt Foci ◽  
Microbiota Composition ◽  
Omics Analysis ◽  
Gut Microbiota Composition

In the AOM-induced precancerous colorectal lesions rat model, HQT inhibits aberrant crypt foci formation mainly by modulating the gut microbiota composition and improving metabolomic disorders.

scholarly journals Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients

2021 ◽  
Vol 22 (17) ◽  
pp. 9549
Author(s):  
Lidia Sánchez-Alcoholado ◽  
Aurora Laborda-Illanes ◽  
Ana Otero ◽  
Rafael Ordóñez ◽  
Alicia González-González ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Fatty Acids ◽  
Gut Microbiota ◽  
Microbial Diversity ◽  
Short Chain Fatty Acids ◽  
Short Chain ◽  
Neoadjuvant Radiochemotherapy ◽  
Microbiota Composition ◽  
Gut Microbiota Composition ◽  
Chain Fatty Acids

Emerging evidence has suggested that dysbiosis of the gut microbiota may influence the drug efficacy of colorectal cancer (CRC) patients during cancer treatment by modulating drug metabolism and the host immune response. Moreover, gut microbiota can produce metabolites that may influence tumor proliferation and therapy responsiveness. In this study we have investigated the potential contribution of the gut microbiota and microbial-derived metabolites such as short chain fatty acids and polyamines to neoadjuvant radiochemotherapy (RCT) outcome in CRC patients. First, we established a profile for healthy gut microbiota by comparing the microbial diversity and composition between CRC patients and healthy controls. Second, our metagenomic analysis revealed that the gut microbiota composition of CRC patients was relatively stable over treatment time with neoadjuvant RCT. Nevertheless, treated patients who achieved clinical benefits from RTC (responders, R) had significantly higher microbial diversity and richness compared to non-responder patients (NR). Importantly, the fecal microbiota of the R was enriched in butyrate-producing bacteria and had significantly higher levels of acetic, butyric, isobutyric, and hexanoic acids than NR. In addition, NR patients exhibited higher serum levels of spermine and acetyl polyamines (oncometabolites related to CRC) as well as zonulin (gut permeability marker), and their gut microbiota was abundant in pro-inflammatory species. Finally, we identified a baseline consortium of five bacterial species that could potentially predict CRC treatment outcome. Overall, our results suggest that the gut microbiota may have an important role in the response to cancer therapies in CRC patients.

scholarly journals The roles of the gut microbiota–miRNA interaction in the host pathophysiology

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Meihong Li ◽  
Wei-Dong Chen ◽  
Yan-Dong Wang
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Fusobacterium Nucleatum ◽  
Biological Processes ◽  
Microbiota Composition ◽  
Host Health ◽  
Health And Disease ◽  
Immune Health ◽  
Review Current ◽  
Gut Microbiota Composition

Abstract The gut microbiota regulates the biological processes of organisms acting like ‘another’ genome, affecting the health and disease of the host. MicroRNAs, as important physiological regulators, have been found to be involved in health and disease. Recently, the gut microbiota has been reported to affect host health by regulating host miRNAs. For example, Fusobacterium nucleatum could aggravate chemoresistance of colorectal cancer by decreasing the expression of miR-18a* and miR-4802. What’s more, miRNAs can shape the gut microbiota composition, ultimately affecting the host's physiology and disease. miR-515-5p and miR-1226-5p could promote the growth of Fusobacterium nucleatum (Fn) and Escherichia coli (E.coli), which have been reported to drive colorectal cancer. Here, we will review current findings of the interactions between the gut microbiota and microRNAs and discuss how the gut microbiota–microRNA interactions affect host pathophysiology including intestinal, neurological, cardiovascular, and immune health and diseases.

Sign in / Sign up

Export Citation Format

Share Document